IRVINE, Calif. – August 20, 2025 –BioDuro, a trusted global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that Christopher Conway, CEO of Bio X Cell, has been appointed to BioDuro's Board of Directors, effective immediately.
"Supported by our investors at Advent International and the Bridgewest Group, BioDuro continues to strengthen its leadership team to drive accelerated growth and innovation across global operations," said Dr. Armin Spura, CEO of BioDuro." We are pleased to welcome Chris to our board. His deep expertise in life sciences and proven leadership in scaling R&D operations will be invaluable as we continue to grow our global footprint and deliver best-in-class solutions to our biotech and pharmaceutical partners."
Mr. Conway has over 25 years of experience in the life sciences industry, including executive roles at New York-based CDMO Curia (formerly AMRI), where he led the company's R&D business unit, and with Johnson & Johnson, where he held several commercial roles. In addition to his current position as CEO of Bio X Cell, the world's leading functional antibody solutions provider specializing in large-scale RUO antibody manufacturing and services, Mr Conway is a board member of the Drug, Chemical & Associated Technologies Association (DCAT). Earlier, he served on the board at Viyash Life Sciences, an integrated end-to-end pharmaceutical company with a presence across niche formulations, APIs and advanced intermediates.
Commenting on his appointment, Christopher Conway said: "I'm honored to join the board of BioDuro and collaborate with such a dynamic team. The company's commitment to scientific excellence and global impact aligns perfectly with my passion for advancing drug discovery and development. I look forward to contributing to its continued success."
About BioDuro
BioDuro, an Advent International portfolio company, is a CRDMO with a 29-year proven track record. Headquartered in Irvine, California, USA, our global presence spans 7 sites across the United States and China, and over 2,000 employees. Specializing in both small and large molecule discovery, development, scale-up, and manufacturing, we offer fully integrated services from early drug discovery to commercial manufacturing across chemistry, biology, drug metabolism and pharmacokinetics (DMPK), drug substance, and drug product.
Media Enquiries
Christina Coby
Associate Director, BioDuro
Email: christina.coby@bioduro.com
Mobile: +1 (619) 414 7409
Chris Halling
Director, Communications & Content, Orientation Marketing
Email: Chris.Halling@orientation.agency
Mobile: +44 (0)7580 041073
Home
